ArticleDermatology and therapy2026
Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)
A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)
Who cites it
1 citing paper in PubMed.
- Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).Pharmacy (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis may increase risk for comorbid diabetes and obesity. Tildrakizumab, an anti-interleukin-23 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis, was evaluated in the pivotal phase 3 trials reSURFACE 1 and reSURFACE 2. This analysis evaluates the effects of comorbid diabetes with and without obesity on the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
methodsThis is a post hoc, pooled subgroup analysis of patients in reSURFACE 1 and reSURFACE 2 grouped by diabetes and obesity status. Patients randomized to tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter, or placebo, were included. The original coprimary endpoints were the proportions of patients achieving a ≥ 75% improvement in Psoriasis Area and Severity Index score (PASI 75 response) and Physician Global Assessment score of 0/1 with ≥ 2-grade improvement (PGA 0/1 response) from baseline at week 12. Safety was assessed from treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
resultsOf 926 patients, 93 had diabetes mellitus. At week 12, regardless of diabetes status, significantly more patients receiving tildrakizumab vs placebo achieved a PASI 75 response (diabetes, 61.4% vs 5.6%; without diabetes, 62.6% vs 5.8%) and PGA 0/1 response (with diabetes, 54.4% vs 2.8%; without diabetes, 56.5% vs 6.2%; all P < 0.0001). Diabetes status did not significantly affect tildrakizumab efficacy at week 28. Patients with diabetes and comorbid obesity had generally similar responses. Although subgroup sizes were small, patients with diabetes and comorbid obesity had numerically higher frequencies of TEAEs and SAEs than those without diabetes.
conclusionsShort-term efficacy of tildrakizumab was maintained in patients with and without diabetes mellitus. A higher frequency of AEs in patients with diabetes and obesity may be attributable to underlying disease and associated higher inflammation.
trial registrationClinicalTrials.gov identifier, NCT01722331 (reSURFACE 1), NCT01729754 (reSURFACE 2).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.